OxCan
Oxford Cancer Analytics (OXcan) is a medtech company focused on transforming cancer treatment through early detection using advanced proteomics and AI. Their DEcancer platform offers minimally invasive blood tests aimed at lung cancer, leveraging machine learning for enhanced accuracy. With significant funding and a multidisciplinary team, OXcan is positioned to make a substantial impact in the cancer diagnostics market, aiming to save lives and improve patient outcomes.
OxCan
Oxford Cancer Analytics (OXcan) is a medtech company focused on transforming cancer treatment through early detection using advanced proteomics and AI. Their DEcancer platform offers minimally invasive blood tests aimed at lung cancer, leveraging machine learning for enhanced accuracy. With significant funding and a multidisciplinary team, OXcan is positioned to make a substantial impact in the cancer diagnostics market, aiming to save lives and improve patient outcomes.
TL;DR
Founded: 2020
Primary focus: Early lung cancer detection (proteomics + ML liquid biopsy)
Latest round: US$11M Series A (announced Jan 9, 2025)
Total funding (reported): ~US$16.7M
Company Overview
Problem Domain
Early cancer detection; diagnostic screening/triage for lung cancer
Founded
2020
Industry
Biotechnology
Funding Track Record
USD 11,000,000
Announced Series A to advance lung cancer test toward commercialisation.
GBP 1.28M
Seed round noted as oversubscribed with participation from institutional and angel investors.
Investor Signal
“Participated by specialist health/impact investors and cancer-focused institutions (e.g., Macmillan Cancer Support, The Francis Crick Institute) alongside VC firms and angels”